Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of azeliragon in mild Alzheimer's disease
2017-004065-27Phase 3Completed
- Sponsor
- vTv Therapeutics
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of azeliragon in Alzheimer's disease (AD), sponsored by vTv Therapeutics. Primary endpoint: Long-term safety and tolerability. Started Jan 2018; status: completed.
02
Drugs
azeliragon
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2017-004065-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004065-27.